Clinical phenotypes of Alzheimer's disease: investigating atrophy patterns and their pathological correlates

Niels Reijner1,2,3, I Frigerio4,5,6, M M A Bouwman4,5,6

  • 1Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1108, Amsterdam, 1081 HZ, Netherlands. n.reijner@amsterdamumc.nl.

PubMed
Abstract

Insights

Alzheimer's disease (AD) brain atrophy is influenced by amyloid-beta (Aβ) and neuro-axonal damage, affecting typical and atypical AD phenotypes differently. Understanding these volume-pathology relationships improves MRI interpretation in AD research and clinical settings.

Area of Science:

  • Neuroimaging
  • Neuropathology
  • Alzheimer's Disease Research

Background:

  • MRI atrophy patterns differentiate Alzheimer's disease (AD) phenotypes (amnestic/typical vs. non-amnestic/atypical).
  • These patterns are crucial for AD diagnosis and clinical trial outcomes.
  • The influence of protein accumulation and neurodegeneration on MRI measurements in AD is not fully understood.

Purpose of the Study:

  • To investigate regional MRI cortical atrophy patterns in typical and atypical AD.
  • To assess the association between these atrophy patterns and key neuropathological markers: amyloid-beta (Aβ), phosphorylated tau (pTau), neuro-axonal degeneration, and microvascular deterioration.

Main Methods:

  • Utilized post-mortem in-situ 3DT1 3T-MRI data from 33 AD (17 typical, 16 atypical) and 16 control brain donors.
  • Collected ante-mortem MRI scans when available, performing regional volume analysis using atlas-based parcellation.
  • Immunostained cortical tissue for Aβ, pTau, neurofilament light (NfL), and collagen IV (COLIV), analyzing associations with linear mixed models.

Main Results:

  • Both AD phenotypes showed temporo-occipital cortical volume loss; typical AD also exhibited parietal lobe loss.
  • Global analysis revealed positive associations between MRI cortical volume and Aβ load, and negative associations with NfL load in AD.
  • Regionally, specific volume-pathology relationships were identified, such as superior parietal gyrus volume correlating with Aβ load in typical AD, and middle frontal gyrus volume with NfL load in atypical AD.

Conclusions:

  • Cortical volume in both AD phenotypes is impacted by Aβ and neuro-axonal damage, with opposing effects.
  • Region-specific differences in volume-pathology relationships exist between typical and atypical AD.
  • Findings enhance the interpretation of MRI data in diverse AD cohorts for research and clinical applications.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310